- Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: PT003; Drug: PT001; Drug: PT005; Drug: Tiotropium inhalation powder
Sponsors: Pearl Therapeutics, Inc.; Pearl Therapeutics, Inc.
Recruiting - verified April 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: PH-797804; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Pulmonary Disease, Chronic Obstructive
Interventions: Drug: tiotropium; Drug: Placebo
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals
Recruiting - verified May 2012 - Conditions: Anesthesia; Neuromuscular Blockade
Interventions: Drug: Remifentanil infusion; Drug: Rocuronium dose + Remifentanil infusion; Drug: Rocuronium dose + Remifentanil infusion; Drug: Rocuronium dose + Remifentanil infusion; Drug: Remifentanil infusion; Drug: Rocuronium dose + Remifentanil infusion; Drug: Rocuronium dose + Remifentanil infusion; Drug: Rocuronium dose + Remifentanil infusion
Sponsors: Covidien; Covidien
Recruiting - verified May 2012 - Condition: Chronic Obstructive Pulmonary Disease
Interventions: Drug: Aclidinium Bromide/Formoterol Fumarate; Drug: Aclidinium Bromide/Formoterol Fumarate; Drug: Aclidinium Bromide; Drug: Formoterol Fumarate; Drug: placebo
Sponsors: Forest Laboratories; Forest Laboratories; Almirall, S.A.
Recruiting - verified March 2012 - Condition: Heart Failure
Intervention: Drug: Pyridostigmine Bromide
Sponsors: New York University School of Medicine; New York University School of Medicine; Nathan Kline Institute for Psychiatric Research; Oklahoma State University Center for Health Sciences; National Heart, Lung, and Blood Institute (NHLBI)
Not yet recruiting - verified August 2011 - Condition: Status Asthmaticus
Interventions: Other: Noninvasive positive pressure ventilation; Other: standard of care
Sponsors: Southern Illinois University; Southern Illinois University
Recruiting - verified February 2012 - Condition: Cholinergic Function
Interventions: Drug: Scopolamine; Drug: Placebo; Drug: Donepezil
Sponsors: Hebrew Rehabilitation Center, Boston; Hebrew Rehabilitation Center, Boston
Recruiting - verified March 2012 - Conditions: Orthostatic Hypotension; Multiple System Atrophy
Interventions: Drug: Droxidopa; Drug: Pyridostigmine Bromide
Sponsors: Mayo Clinic; Mayo Clinic
Recruiting - verified December 2011 - Condition: Asthma
Interventions: Drug: Tiotropium; Drug: Salmeterol; Drug: Formoterol
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; Olmsted Medical Center; American Academy of Family Physicians National Research Network; Harvard Clinical Research Institute
Recruiting - verified March 2012 - Condition: Asthma
Interventions: Drug: tiotropium Respimat low dose; Drug: tiotropium Respimat high dose; Drug: placebo Respimat
Sponsors: Boehringer Ingelheim Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals; Pfizer
Recruiting - verified May 2012 - Condition: Depression
Intervention: Drug: Scopolamine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012 - Conditions: Neoplasms; Constipation; Opioid-Related Disorders
Intervention: Drug: Methylnaltrexone bromide
Sponsors: University of Vermont; University of Vermont
Recruiting - verified March 2012 - Condition: Asthma
Intervention: Drug: salmeterol
Sponsors: Nemours Children's Clinic; Nemours Children's Clinic; University of Florida
Recruiting - verified August 2011 - Condition: Opioid-Induced Constipation
Interventions: Drug: Methylnaltrexone bromide; Drug: Placebo
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals; Progenics Pharmaceuticals, Inc.
Recruiting - verified January 2012 - Condition: Opioid-Induced Constipation
Intervention: Drug: Methylnaltrexone bromide
Sponsors: Salix Pharmaceuticals; Salix Pharmaceuticals; Progenics Pharmaceuticals, Inc.
Recruiting - verified January 2012 - Conditions: Unipolar Depression; Bipolar Depression
Intervention: Drug: Scopolamine
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified February 2012 - Conditions: Autonomic Failure; Orthostatic Hypotension
Interventions: Drug: Atomoxetine; Drug: Acarbose; Drug: Pyridostigmine Bromide; Drug: Yohimbine; Drug: Midodrine HCl; Drug: placebo; Drug: Modafinil; Drug: Octreotide; Other: water intake; Drug: Diphenhydramine Hydrochloride; Drug: Ranitidine HCL; Drug: Tranylcypromine; Drug: Ergotamine/ Caffeine; Drug: Celecoxib; Drug: Pseudoephedrine; Drug: Methylphenidate; Drug: Indomethacin; Drug: Ibuprofen; Drug: Oxymetazoline 0.05% nasal solution; Dietary Supplement: Bovril; Drug: Acetazolamide; Drug: Rivastigmine tartrate; Drug: Carbidopa/levodopa; Device: abdominal binder; Device: abdominal binder (sham)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Conditions: Mood Disorders; Healthy; Unipolar Depression; Bipolar Depression
Intervention: Drug: Transderm Scopolamine
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Mental Health (NIMH)
Recruiting - verified July 2011
 |
Bromides Clinical Trials |
